SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to its strong community and growing holder count, signaling increasing interest and conviction. The community is actively discussing the potential for a major rally, driven by the expectation of a significant move in the dawg coin sector. Many believe $KENDU.X is undervalued and primed for substantial growth, emphasizing its real-world applications and brand development.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the community rallies around its position as the first meme coin on Bitcoin, emphasizing its fair launch and strong community-driven growth. Discussion highlights its unique utility in strengthening the Bitcoin network through miner fees, setting it apart from other meme coins. Some believe $DOG.X has the potential to outperform other meme coins like $DOGE.X.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending due to positive updated Phase 3 HARMONi data for its lung cancer drug, ivonescimab, sparking optimism about its potential. The community is focused on the drug's OS benefit and its competitive efficacy compared to existing treatments, while also debating the validity and interpretation of trial data. Some investors are speculating about a potential acquisition or partnership, particularly with AstraZeneca, driving further interest in the stock.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses potential catalysts, including speculation around a Dogecoin ETF and its impact on price. Sentiment is focused on the potential for significant gains, with some looking toward the token reaching the $1 mark. The conversation also includes discussion around Dogecoin's relationship with other meme coins and their respective ecosystems.

DOVU

DOVU.X is trending as the community highlights its staking rewards and potential in the Real World Asset (RWA) space, particularly due to its "Trust Operating System." Recent news around partnerships and deals related to carbon credits and ecological projects may be acting as a catalyst. Community members are actively discussing its association with Hedera and potential for significant growth.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the Bitcoin memecoin gains traction within the crypto community, with many touting its fair launch and strong community backing. Conversation highlights its potential to become the meme face of Bitcoin and draw comparisons to other popular memecoins. Community members are emphasizing its organic growth and decentralized nature.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

Children's Place is trending due to recent earnings and guidance, with discussions centered on a potential short squeeze given its high short interest. Community members are debating the company's turnaround efforts and the impact of new management, with some highlighting positive comparable DTC sales and others expressing concerns about financials and potential bankruptcy. The stock's low float and high short interest are fueling speculation about a significant price movement.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a recent land sale agreement, potentially boosting its NAV, which has captured the attention of traders. The stock's low float is fueling discussions of a potential squeeze, with community members actively watching for breakout levels. Some are betting on a significant upward move, drawing comparisons to other low-float runners.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending as traders discuss its recent listing on Coinbase and potential for high gains, with some community members pointing to its AI-powered trading platform and the possibility of new partnerships. Bullish sentiment is fueled by the hope of 'dropping zeros' and achieving significant market cap growth. Others are comparing it to similar tokens that have experienced substantial pumps.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members discuss its potential involvement in upcoming military programs and the recent partnership with Airbus for European markets. Bullish sentiment is fueled by the company's positioning in the defense sector, particularly related to drone technology and hypersonic systems. Some investors are speculating about future contracts and a potential stock split, while others are noting technical indicators and potential resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its investigational drug Vepdegestrant.Wells Fargo believes Pfizer's (PFE) waning interest in Vepdegestrant could lead to Arvinas getting it back, but given where the stock is trading, this seems priced in. The firm noted that Arvinas won't launch the drug solo and added that with runway to the second half of 2028, focus shifts to its early-stage pipeline, which can create value.Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of Vepdegestrant in July 2021. Wells lowered its price target on <a href="https://stocktwits.com/symbol/ARVN">Arvinas</a> to $16 from $19 while keeping an ‘Overweight’ rating on the shares.&nbsp;On Stocktwits, retail sentiment around Arvinas fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_10_00_16_AM_png_a0b59de82a.webp" alt="ARVN's Sentiment Meter and Message Volume as of 10 a.m. ET on Aug. 7, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>ARVN's Sentiment Meter and Message Volume as of 10 a.m. ET on Aug. 7, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright, however, raised its price target on Arvinas to $24 from $18 while keeping a ‘Buy’ rating on the shares. The firm sees a path forward for Vepdegestrant and cited the company's pipeline development and progress for the target increase.Arvinas and its partner Pfizer submitted a new drug application for Vepdegestrant to the U.S. Food and Drug Administration in June for the treatment of certain types of advanced or metastatic breast cancer previously treated with endocrine-based therapy.The application was based on data from a late-stage trial that evaluated Vepdegestrant versus the popular breast cancer medicine Fulvestrant. While the trial demonstrated improvement in median progression-free survival (PFS) compared to Fulvestrant, it did not reach statistical significance.In the second quarter, Arvinas recorded a revenue of $22.4 million, down from $76.5 million in the corresponding quarter of 2024. The company pegged the drop in part to a fall in revenue from the agreement with Pfizer related to the removal of certain late-stage combination trials of Vepdegestrant with Pfizer’s investigational drugs from the development plan.ARVN stock is down by 68% this year and by about 75% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-warns-higher-us-tariff-impact-for-fy26/chrmEbQRdd6">Toyota Warns Higher US Tariff Impact For FY26: Retail Sees No Reason To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach

While Wells Fargo remains pessimistic on Vepdegestrant’s future, H.C. Wainwright is hopeful. 

Equity

While Wells Fargo remains pessimistic on Vepdegestrant’s future, H.C. Wainwright is hopeful. 


Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales. 

Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of +3.45% and -53.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.76	--	--	N/A
Q2 '25	-$0.94	-$0.84	10.17%	BEAT
Q1 '25	-$0.96	$1.14	218.15%	BEAT
Q4 '24	-$0.96	-$0.63	34.06%	BEAT
Q3 '24	-$0.84	-$0.68	19.30%	BEAT

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ARVN News

ARVN Arvinas Inc